Integrating tumor microenvironment modulation with nanocarrier engineering for enhanced tumor-targeted delivery.

The tumor microenvironment (TME) imposes vascular, stromal, metabolic, and immune barriers that restrict nanoparticle (NP) extravasation, interstitial penetration, cellular access, and therapeutic activity in solid tumors. Because the dominant barrier and the delivery step most directly constrained vary across tumor types, platforms, and experimental models, neither TME modulation nor nanocarrier optimization can be treated as a universal solution. This review critically examines vascular, extracellular matrix (ECM), hypoxia/acidosis, and immune-modulating strategies together with nanocarrier size, shape, surface charge, targeting ligands, stimuli-responsive or temporally coordinated behavior, and particle mechanics. To move beyond parallel descriptions of these topics, we organize representative tumor contexts into four barrier phenotypes-stroma/ECM-dominant, vascular-dominant, hypoxia/acidosis-dominant, and immunosuppressive-and evaluate each phenotype according to its principal delivery limitation, the transport conditions created by TME modulation, and potentially compatible nanocarrier-design considerations. The mappings distinguish stronger direct support, context-dependent evidence, and the absence of direct barrier-specific comparisons. Particular attention is given to particle mechanics, whose apparent effects are often coupled to composition, size, architecture, degradation, protein-corona formation, and measurement method and remain predominantly preclinical. Clinical studies are interpreted as regimen-level evidence unless barrier modification or intra-tumoral NP deposition was directly measured. This barrier-phenotype-guided framework therefore provides a conditional basis for integrating TME modulation with nanocarrier engineering without implying a universal or clinically validated formulation prescription.